Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO)

dc.contributor.authorUnal, Olcun Umit
dc.contributor.authorOztop, Ilhan
dc.contributor.authorYasar, Nurgul
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorOzatli, Tahsin
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorSevinc, Alper
dc.date.accessioned2024-04-24T17:11:24Z
dc.date.available2024-04-24T17:11:24Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackgroundSoft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outcomes. MethodsThe medical records of 109 patients with thoracic STSs who were treated between 2003 and 2013 were retrospectively reviewed. Patients' survival rates were analyzed and potential prognostic factors evaluated. ResultsThe median follow-up period was 29 months (range: 1-121 months). STSs were most frequently localized on the chest wall (n = 42; 38.5%) and lungs (n = 42; 38.5%). The most common histological types were malignant fibrous histiocytoma (n = 23; 21.1%), liposarcoma (n = 17; 15.6%), and leiomyosarcoma (n = 16; 14.7%). The median survival time of all patients was 40.3 months (95% confidence interval, 14.22-66.37 months), with one and five-year survival rates of 93.4% and 63.5%, respectively. Univariate analysis of all groups revealed that metastatic stage, unresectability, tumor diameter of >10cm, tumor location other than the chest wall, and grade 3 diseases were predictable of poor survival. However, only grade 3 diseases and tumor location other than the chest wall were confirmed by multivariate analysis as poor prognostic factors. ConclusionsPrimary thoracic STSs are rarely seen malignant tumors. Our results indicated that patients with low-grade tumors and those localized on the chest wall often experienced better survival outcomes.en_US
dc.identifier.doi10.1111/1759-7714.12150
dc.identifier.endpage90en_US
dc.identifier.issn1759-7706
dc.identifier.issn1759-7714
dc.identifier.issue1en_US
dc.identifier.pmid26273340
dc.identifier.scopus2-s2.0-84920390827
dc.identifier.scopusqualityQ2
dc.identifier.startpage85en_US
dc.identifier.urihttps://doi.org/10.1111/1759-7714.12150
dc.identifier.urihttps://hdl.handle.net/11468/17482
dc.identifier.volume6en_US
dc.identifier.wosWOS:000347541900014
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofThoracic Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPrimary Thoracic Soft Tissue Sarcomaen_US
dc.subjectPrognostic Factorsen_US
dc.subjectTreatmenten_US
dc.titleClinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO)en_US
dc.titleClinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO)
dc.typeArticleen_US

Dosyalar